

## Simplifying Progress

This is Sartorius

Company Presentation | 2021

SVIDUL

# Partner of life science research and the biopharmaceutical industry

## Our mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.





#### Our vision

We are a magnet and dynamic platform for pioneers and leading experts in our field. We bring creative minds together for a common goal: technological breakthroughs that lead to better health for more people.



## Pacesetter for more than 150 years

- 1870 Florenz Sartorius, a 24-year-old, continues to develop a weighing technology that reduces the time for balance beam stabilization, substantially accelerating lab experiments as a result.
- 1927 A joint venture with Nobel Prize laureate Richard Zsigmondy expands the Sartorius product portfolio to include membrane filters.

Back then as today, our innovative product solutions are helping to accelerate research work, simplify manufacturing processes and improve quality of results.





## Sartorius in brief

## 60+

Locations worldwide, headquartered in Göttingen, Germany

2 10,600+ Employees<sup>1</sup>


€ ~€2.3bn Sales revenue<sup>1</sup>

29.6%
EBITDA margin<sup>1,2</sup>

## ‴\_\_~€23.6bn

Sartorius AG market capitalization; included in relevant indices in Germany

1 As of December 31, 2020, 2 Underlying EBITDA






Strong company values are the basis of all our activities







# Strategic focus on the biopharma market






## Attractive market environment with strong growth opportunities

ළු	Favorable demographics	<b>~9bn</b> people by 2050; >2bn 60 years or older	
ß	Rise of biosimilars	~30% CAGR for biosimilar sales in 2020-2025	<b>~10%</b> CAGR for biopharma market 2020–2025
	Strong R&D pipeline; advances in gene and cell therapy	>40% share of biologics in the pharma R&D pipeline	



# What are biopharmaceuticals?



### Advantages

- First-time or improved treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism
- Targets only diseased cells; fewer side effects
- New vaccines



# Our products are widely used in the development and production of biologics against COVID-19

200+ companies developing coronavirus vaccines



The majority work with Sartorius products



# Pandemic crisis with significantly different effects

- High demand related to the development and production of vaccines and therapeutics against COVID-19; consequences from delays in other clinical trials not clear yet
- Impact by softer macroeconomic environment; positive effects on products that are used for testing




## The development and manufacture of biopharmaceuticals are complex





## Only one out of 10,000 new drug candidates reaches the market



Schematic example of biologic drug discovery with data from the Association of the British Pharmaceutical Industry



## The consequence: Biotech medications are extremely expensive

## **HUMIRA®**

Annual revenue of \$18 billion; is used to treat rheumatism and other inflammatory autoimmune diseases, such as Crohn's disease and psoriasis

Manufacturer: Abbvie



Cost per annual treatment €21,300 in Germany

Source: Abbvie

First biosimilars out on the market:

- Imraldi<sup>®</sup> from Biogen up to **40%** less expensive
- Hyrimoz<sup>®</sup> from Sandoz around **21%** less expensive
- Amgevita<sup>®</sup> from Amgen about 18% less expensive

## ZOLGENSMA®

Currently the world's most expensive medical drug; gene therapy used to treat spinal muscular atrophy

### Manufacturer: Novartis



Cost per treatment **\$2,100,000** in the U.S.

Source: Novartis



## Our ambition: Reduce costly trial & error in drug discovery


### Our laboratory tools support researchers ...

- ... in understanding diseases
- $\ldots$  in conducting experiments and evaluating their data
- ... in identifying the right molecules and developing new medicines





# Our solution: Technologies to accelerate drug discovery and development





# Our goal: Simplify manufacturing of biopharmaceuticals

Our technologies empower engineers in the biopharma industry to ...

- ... set up robust, flexible and safe processes for industrial production
- ... reduce setup costs

... enhance product yield






# Our solution: Innovative technologies for all phases of drug production

## Products

Scalable single-use technologies for the production of biopharmaceuticals and digital tools for biopharma data analytics


## Application areas

- Biopharmaceutical manufacturing
- Quality control and testing





## The widest offering of solutions in the industry





# Flexible production systems are becoming more and more prevalent

#### Classic stainless steel plants



- High initial investment outlay
- High cleaning effort and expense
- Risk of contamination

### Flexible systems with sterile bags




- + Faster setup and lower investment throughout the entire life cycle
- Lower consumption of water and energy
- + Reduced risk of cross-contamination



# Data analytics has huge potential for the biopharmaceutical industry

Sartorius supports its customers in the digitalization and automation of their processes with its leading software for analysis of bioprocess data.

- Enhanced process control and robustness
- Improved product quality
- ✓ Predictive process control
- Powerful solutions for modeling and optimizing development and manufacturing
- Helps provide insights derived from complex data sets






## Leading market positions worldwide in both segments

	Procede STR <sup>®</sup>						
Fluid management	Fermentation	Filtration	Purification	Lab balances	Microbiological analysis	Lab filtration	Pipettes
#1	#1	#3	#3	#2	#2	#3	#4



## Acquisitions strengthen and differentiate the Sartorius portfolio




#### Acquired technologies include

- Automated multi-parallel microbioreactor
- Aseptic single-use sampling system
- Cell line and process development services
- Automated single-use centrifugation
- Bioprocessing software
- Cell culture media

- Chromatography and tangential flow filtration systems; microcarriers
- Multiple systems for cell and protein analysis



## Sales revenue has doubled over the last five years



Sales growth and CAGR 2011-20 for continued operations, in constant currencies; 1 Excluding extraordinary items



## Sartorius 2025 ambition and initiatives

### Strategic initiatives

#### Regional

- Participate in strong Chinese market growth
- Continue to outperform the important U.S. market


#### Portfolio

- Add high-impact innovations, e.g., digital tools
- Enhance process development capabilities
- Expand into adjacent applications

#### Operations

- Accelerate workflows across the organization through digitalization
- Extend manufacturing base in Asia

2025 targets are based on 2017 currency exchange rates; non-organic sales growth is taken into account for companies acquired from 2018 onwards; EBITDA excluding extraordinary items;



SVLY2VS

# Expansion of production capacities will be significantly accelerated and extended

#### Guxhagen, Germany

Capacity expansion for bioreactors and other equipment for the production of biopharmaceuticals; integration of a Customer Interaction Center





#### **Göttingen, Germany** New facility for membrane production; 12,000 m<sup>2</sup> extension for existing R&D capacities



Marlborough, MA, USA New Customer Interaction Center



Yauco, Puerto Rico Buildup of cell culture media production; expansion of membrane, filter and bag manufacture in Yauco





#### New clean production filter manu Customer

**Beijing, China** New cleanroom for bag production; more space for filter manufacture; new Customer Interaction Center

#### Songdo, South Korea

Construction of a new 25,000 m<sup>2</sup> site for cell culture media production, laboratories and application center





